Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.48 -3.2%	$0.41	$0.30 ▼ $10.62	$69.70M	1.97	2.63 million shs	1.01 million shs
BLRX BioLineRx	$3.74 -2.3%	$4.37	$2.30 ▼ $31.62	$15.93M	1.15	366,741 shs	57,117 shs
ICCC ImmuCell	$5.90 -3.4%	$6.52	$3.34 ▼ $7.60	$53.34M	0.3	20,120 shs	11,348 shs
IMA ImageneBio	$14.04 -4.5%	$16.00	$11.65 ▼ $23.28	$56.44M	0.51	13,866 shs	9,489 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	+4.36%	+11.33%	+8.25%	+14.81%	-91.45%
BLRX BioLineRx	+3.23%	+2.96%	-14.32%	+5.22%	-87.03%
ICCC ImmuCell	+0.16%	-8.26%	-7.70%	+10.29%	+66.49%
IMA ImageneBio	+3.52%	-0.27%	-3.54%	+8.41%	-28.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLT Applied Therapeutics	4.2093 of 5 stars	3.3	3.0	4.7	2.8	1.7	0.6
BLRX BioLineRx	3.3215 of 5 stars	3.8	5.0	0.0	2.3	0.0	1.3
ICCC ImmuCell	0.5305 of 5 stars	0.0	5.0	0.0	1.7	0.0	0.0
IMA ImageneBio	3.1493 of 5 stars	3.3	0.0	0.0	2.7	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLT Applied Therapeutics	2.50	Moderate Buy	$6.10	1,160.33% Upside
BLRX BioLineRx	3.50	Strong Buy	$26.00	595.19% Upside
ICCC ImmuCell	0.00	N/A	N/A	N/A
IMA ImageneBio	2.50	Moderate Buy	$35.50	152.85% Upside

Current Analyst Ratings Breakdown

Latest BLRX, APLT, ICCC, and IMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/25/2025	IMA ImageneBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$25.00 ➝ $23.00
6/17/2025	BLRX BioLineRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/30/2025	BLRX BioLineRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/28/2025	BLRX BioLineRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLT Applied Therapeutics	$121K	576.05	N/A	N/A	$0.49 per share	0.99
BLRX BioLineRx	$28.94M	0.55	N/A	N/A	$4.04 per share	0.93
ICCC ImmuCell	$26.49M	2.01	$0.06 per share	94.92	$3.09 per share	1.91
IMA ImageneBio	$9.16M	6.16	N/A	N/A	$31.33 per share	0.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLT Applied Therapeutics	-$105.62M	-$0.45	N/A	N/A	N/A	N/A	-354.24%	-144.16%	11/6/2025 (Estimated)
BLRX BioLineRx	-$9.22M	-$8.80	N/A	N/A	N/A	-45.34%	-54.79%	-17.36%	N/A
ICCC ImmuCell	-$2.16M	$0.19	31.05	∞	N/A	6.23%	6.37%	3.91%	N/A
IMA ImageneBio	-$49.23M	-$7.68	N/A	N/A	N/A	N/A	-23.94%	-21.62%	N/A

Latest BLRX, APLT, ICCC, and IMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	BLRX BioLineRx	-$0.35	-$1.00	-$0.65	-$1.00	$0.66 million	$0.30 million
8/14/2025	Q2 2025	ICCC ImmuCell	N/A	$0.06	N/A	$0.06	N/A	$6.45 million
8/13/2025	Q2 2025	APLT Applied Therapeutics	-$0.17	-$0.15	+$0.02	-$0.15	$0.42 million	N/A
7/24/2025	Q2 2025	IMA ImageneBio	-$0.14	-$0.06	+$0.08	-$0.06	N/A	N/A
5/27/2025	Q1 2025	BLRX BioLineRx	-$0.84	$1.39	+$2.23	$1.39	$7.72 million	$11.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A
IMA ImageneBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLT Applied Therapeutics	N/A	1.94	1.94
BLRX BioLineRx	0.37	2.27	2.04
ICCC ImmuCell	0.30	4.12	2.21
IMA ImageneBio	N/A	13.52	13.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLT Applied Therapeutics	98.31%
BLRX BioLineRx	1.56%
ICCC ImmuCell	13.47%
IMA ImageneBio	75.00%

Insider Ownership

Company	Insider Ownership
APLT Applied Therapeutics	1.60%
BLRX BioLineRx	1.10%
ICCC ImmuCell	5.60%
IMA ImageneBio	5.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLT Applied Therapeutics	30	144.01 million	141.71 million	Optionable
BLRX BioLineRx	40	4.26 million	4.22 million	Optionable
ICCC ImmuCell	70	9.04 million	8.53 million	Not Optionable
IMA ImageneBio	70	4.02 million	3.78 million	Not Optionable

BLRX, APLT, ICCC, and IMA Headlines

Recent News About These Companies

ImageneBio (IMA) Expected to Announce Earnings on Thursday

August 12, 2025 | americanbankingnews.com

Ikena Oncology (IMA) Projected to Post Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade

August 5, 2025 | zacks.com

Q3 EPS Estimates for Ikena Oncology Lifted by William Blair

August 4, 2025 | marketbeat.com

William Blair Estimates Ikena Oncology FY2029 Earnings

August 2, 2025 | marketbeat.com

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Ikena Oncology, Inc. (NASDAQ:IMA) Director David P. Bonita Buys 83,611 Shares

July 31, 2025 | marketbeat.com

Insider Buying: Ikena Oncology, Inc. (NASDAQ:IMA) Director Acquires 267,556 Shares of Stock

July 31, 2025 | marketbeat.com

Ikena Oncology, Inc. (NASDAQ:IMA) Director Purchases $2,499,968.90 in Stock

July 31, 2025 | insidertrades.com

Ikena Oncology (NASDAQ:IMA) Stock Price Down 7% - What's Next?

July 30, 2025 | marketbeat.com

Ikena Oncology (NASDAQ:IKNA) Issues Earnings Results

July 27, 2025 | marketbeat.com

Ikena Oncology (NASDAQ:IKNA) Given New $23.00 Price Target at Wedbush

July 26, 2025 | marketbeat.com

Ikena Oncology Inc trading halted, news pending

July 26, 2025 | msn.com

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

July 25, 2025 | globenewswire.com

Ikena Oncology shares climb as Kristin Yarema named CEO of soon-to-merge ImageneBio

July 24, 2025 | msn.com

Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company

July 24, 2025 | investing.com

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

July 23, 2025 | globenewswire.com

Ikena Oncology, Inc.: Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

July 16, 2025 | finanznachrichten.de

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

July 15, 2025 | globenewswire.com

Ikena Oncology, Inc.: Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote "FOR" Proposed Merger with Inmagene Biopharmaceuticals

July 15, 2025 | finanznachrichten.de

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals

July 11, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX, APLT, ICCC, and IMA Company Descriptions

Applied Therapeutics NASDAQ:APLT

$0.48 -0.02 (-3.20%)

Closing price 04:00 PM Eastern

Extended Trading

$0.50 +0.01 (+2.48%)

As of 06:47 PM Eastern

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

BioLineRx NASDAQ:BLRX

$3.74 -0.09 (-2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$3.82 +0.09 (+2.27%)

As of 06:26 PM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

ImmuCell NASDAQ:ICCC

$5.90 -0.21 (-3.44%)

Closing price 04:00 PM Eastern

Extended Trading

$5.94 +0.04 (+0.68%)

As of 04:04 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

ImageneBio NASDAQ:IMA

$14.04 -0.66 (-4.49%)

As of 04:00 PM Eastern

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time